Importance: Biomarkers for chronic traumatic encephalopathy (CTE) are currently lacking. The radiotracer fluorine F 18-labeled (18F)-flortaucipir (FTP) detects tau pathology in Alzheimer disease, and positron emission tomography (PET) with FTP shows elevated binding in individuals at risk for CTE. No study, however, has assessed the correlation between in vivo FTP PET and postmortem tau in CTE. Objective: To assess the regional association between in vivo FTP binding and postmortem tau pathology in a patient with pathologically confirmed CTE. Design, Setting, and Participants: A white male former National Football League player with 17 years of US football exposure was clinically diagnosed with traumatic encephalopathy syndrome at a neurology tertiary referral center. 18F-Fludeoxyglucose, carbon 11-labeled Pittsburgh compound B, and FTP PET were performed 52 months prior to death, and magnetic resonance imaging, 50 months prior to death. Brain images were assessed qualitatively for abnormalities blinded to autopsy data. Autopsy was performed using a neurodegenerative research protocol. The FTP standardized uptake value ratios (inferior cerebellar gray reference region) and W-score (age-adjusted z-score) maps were compared with phosphorylated tau immunohistochemical analysis with monoclonal antibody CP13. Main Outcomes and Measures: Qualitative and quantitative comparisons between antemortem FTP PET and tau pathology at autopsy. Results: Flortaucipir uptake was distributed in a patchy, frontotemporal-predominant pattern that overlapped with regions showing neurodegeneration on magnetic resonance imaging and hypometabolism on 18F-fludeoxyglucose PET. Pathological assessment revealed stage 4 CTE; limbic argyrophilic grain disease; stage 2 limbic-predominant, age-related transactive response DNA-binding protein 43 encephalopathy; and Braak neurofibrillary tangle stage 3. 18F-Flortaucipir W-maps matched areas of high postmortem tau burden in left fusiform and inferior temporal gyri and juxtacortical frontal white matter. High FTP W-scores with low tau burden were found in the basal ganglia, thalamus, motor cortex, and calcarine cortex. No regions with low FTP W-scores corresponded to areas with high pathological tau burden. A modest correlation, which did not reach statistical significance (ρ = 0.35, P = .17), was found between FTP standardized uptake value ratio and tau area fraction at the regional level. Conclusions and Relevance: In this patient, FTP PET findings during life showed a modest correspondence with postmortem pathology in CTE. These findings suggest that FTP may have limited utility as a tau biomarker in CTE.
Importance: Biomarkers for chronic traumatic encephalopathy (CTE) are currently lacking. The radiotracer fluorine F 18-labeled (18F)-flortaucipir (FTP) detects tau pathology in Alzheimer disease, and positron emission tomography (PET) with FTP shows elevated binding in individuals at risk for CTE. No study, however, has assessed the correlation between in vivo FTP PET and postmortem tau in CTE. Objective: To assess the regional association between in vivo FTP binding and postmortem tau pathology in a patient with pathologically confirmed CTE. Design, Setting, and Participants: A white male former National Football League player with 17 years of US football exposure was clinically diagnosed with traumatic encephalopathy syndrome at a neurology tertiary referral center. 18F-Fludeoxyglucose, carbon 11-labeled Pittsburgh compound B, and FTP PET were performed 52 months prior to death, and magnetic resonance imaging, 50 months prior to death. Brain images were assessed qualitatively for abnormalities blinded to autopsy data. Autopsy was performed using a neurodegenerative research protocol. The FTP standardized uptake value ratios (inferior cerebellar gray reference region) and W-score (age-adjusted z-score) maps were compared with phosphorylated tau immunohistochemical analysis with monoclonal antibody CP13. Main Outcomes and Measures: Qualitative and quantitative comparisons between antemortem FTP PET and tau pathology at autopsy. Results:Flortaucipir uptake was distributed in a patchy, frontotemporal-predominant pattern that overlapped with regions showing neurodegeneration on magnetic resonance imaging and hypometabolism on 18F-fludeoxyglucose PET. Pathological assessment revealed stage 4 CTE; limbic argyrophilic grain disease; stage 2 limbic-predominant, age-related transactive response DNA-binding protein 43 encephalopathy; and Braak neurofibrillary tangle stage 3. 18F-Flortaucipir W-maps matched areas of high postmortem tau burden in left fusiform and inferior temporal gyri and juxtacortical frontal white matter. High FTP W-scores with low tau burden were found in the basal ganglia, thalamus, motor cortex, and calcarine cortex. No regions with low FTP W-scores corresponded to areas with high pathological tau burden. A modest correlation, which did not reach statistical significance (ρ = 0.35, P = .17), was found between FTP standardized uptake value ratio and tau area fraction at the regional level. Conclusions and Relevance: In this patient, FTP PET findings during life showed a modest correspondence with postmortem pathology in CTE. These findings suggest that FTP may have limited utility as a tau biomarker in CTE.
Authors: Robert A Stern; Charles H Adler; Kewei Chen; Michael Navitsky; Ji Luo; David W Dodick; Michael L Alosco; Yorghos Tripodis; Dhruman D Goradia; Brett Martin; Diego Mastroeni; Nathan G Fritts; Johnny Jarnagin; Michael D Devous; Mark A Mintun; Michael J Pontecorvo; Martha E Shenton; Eric M Reiman Journal: N Engl J Med Date: 2019-04-10 Impact factor: 91.245
Authors: Rik Ossenkoppele; Daniel R Schonhaut; Michael Schöll; Samuel N Lockhart; Nagehan Ayakta; Suzanne L Baker; James P O'Neil; Mustafa Janabi; Andreas Lazaris; Averill Cantwell; Jacob Vogel; Miguel Santos; Zachary A Miller; Brianne M Bettcher; Keith A Vossel; Joel H Kramer; Maria L Gorno-Tempini; Bruce L Miller; William J Jagust; Gil D Rabinovici Journal: Brain Date: 2016-03-08 Impact factor: 13.501
Authors: Salvatore Spina; Jesse A Brown; Jersey Deng; Raquel C Gardner; Alissa L Nana; Ji-Hye L Hwang; Stephanie E Gaus; Eric J Huang; Joel H Kramer; Howie J Rosen; John Kornak; John Neuhaus; Bruce L Miller; Lea T Grinberg; Adam L Boxer; William W Seeley Journal: Brain Date: 2019-07-01 Impact factor: 13.501
Authors: Joel H Kramer; Jennifer Jurik; Sharon J Sha; Kate P Rankin; Howard J Rosen; Julene K Johnson; Bruce L Miller Journal: Cogn Behav Neurol Date: 2003-12 Impact factor: 1.600
Authors: Marta Marquié; Marc D Normandin; Charles R Vanderburg; Isabel M Costantino; Elizabeth A Bien; Lisa G Rycyna; William E Klunk; Chester A Mathis; Milos D Ikonomovic; Manik L Debnath; Neil Vasdev; Bradford C Dickerson; Stephen N Gomperts; John H Growdon; Keith A Johnson; Matthew P Frosch; Bradley T Hyman; Teresa Gómez-Isla Journal: Ann Neurol Date: 2015-09-25 Impact factor: 10.422
Authors: Philip H Montenigro; Christine M Baugh; Daniel H Daneshvar; Jesse Mez; Andrew E Budson; Rhoda Au; Douglas I Katz; Robert C Cantu; Robert A Stern Journal: Alzheimers Res Ther Date: 2014-09-24 Impact factor: 6.982
Authors: Ann C McKee; Nigel J Cairns; Dennis W Dickson; Rebecca D Folkerth; C Dirk Keene; Irene Litvan; Daniel P Perl; Thor D Stein; Jean-Paul Vonsattel; William Stewart; Yorghos Tripodis; John F Crary; Kevin F Bieniek; Kristen Dams-O'Connor; Victor E Alvarez; Wayne A Gordon Journal: Acta Neuropathol Date: 2015-12-14 Impact factor: 17.088
Authors: Orit H Lesman-Segev; Renaud La Joie; Melanie L Stephens; Ida Sonni; Richard Tsai; Viktoriya Bourakova; Adrienne V Visani; Lauren Edwards; James P O'Neil; Suzanne L Baker; Raquel C Gardner; Mustafa Janabi; Kiran Chaudhary; David C Perry; Joel H Kramer; Bruce L Miller; William J Jagust; Gil D Rabinovici Journal: Neuroimage Clin Date: 2019-10-17 Impact factor: 4.881
Authors: Michael L Alosco; Yi Su; Thor D Stein; Eric M Reiman; Ann C McKee; Robert A Stern; Hillary Protas; Jonathan D Cherry; Charles H Adler; Laura J Balcer; Charles Bernick; Surya Vamsi Pulukuri; Bobak Abdolmohammadi; Michael J Coleman; Joseph N Palmisano; Yorghos Tripodis; Jesse Mez; Gil D Rabinovici; Kenneth L Marek; Thomas G Beach; Keith A Johnson; Bertrand Russell Huber; Inga Koerte; Alexander P Lin; Sylvain Bouix; Jeffrey L Cummings; Martha E Shenton Journal: Eur J Nucl Med Mol Imaging Date: 2022-09-24 Impact factor: 10.057
Authors: David N Soleimani-Meigooni; Leonardo Iaccarino; Renaud La Joie; Suzanne Baker; Viktoriya Bourakova; Adam L Boxer; Lauren Edwards; Rana Eser; Maria-Luisa Gorno-Tempini; William J Jagust; Mustafa Janabi; Joel H Kramer; Orit H Lesman-Segev; Taylor Mellinger; Bruce L Miller; Julie Pham; Howard J Rosen; Salvatore Spina; William W Seeley; Amelia Strom; Lea T Grinberg; Gil D Rabinovici Journal: Brain Date: 2020-12-05 Impact factor: 13.501
Authors: Natasha Krishnadas; Vincent Doré; Fiona Lamb; Colin Groot; Paul McCrory; Rodney Guzman; Rachel Mulligan; Kun Huang; Meaghan O'Donnell; Jennie Ponsford; Malcolm Hopwood; Victor L Villemagne; Christopher C Rowe Journal: Front Neurol Date: 2020-12-22 Impact factor: 4.003
Authors: Michael L Alosco; Megan L Mariani; Charles H Adler; Laura J Balcer; Charles Bernick; Rhoda Au; Sarah J Banks; William B Barr; Sylvain Bouix; Robert C Cantu; Michael J Coleman; David W Dodick; Lindsay A Farrer; Yonas E Geda; Douglas I Katz; Inga K Koerte; Neil W Kowall; Alexander P Lin; Daniel S Marcus; Kenneth L Marek; Michael D McClean; Ann C McKee; Jesse Mez; Joseph N Palmisano; Elaine R Peskind; Yorghos Tripodis; Robert W Turner; Jennifer V Wethe; Jeffrey L Cummings; Eric M Reiman; Martha E Shenton; Robert A Stern Journal: Alzheimers Res Ther Date: 2021-08-12 Impact factor: 8.823
Authors: Adam Martersteck; Ivan Ayala; Daniel T Ohm; Callen Spencer; Christina Coventry; Sandra Weintraub; Eileen H Bigio; M -Marsel Mesulam; Changiz Geula; Emily Rogalski Journal: Acta Neuropathol Commun Date: 2022-08-09 Impact factor: 7.578